1-Biphenyl-4-ylmethyl-butylamine | 121804-28-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Biphenyl-4-ylmethyl-butylamine
• 英文别名: 1-(4-Phenylphenyl)pentan-2-amine
• CAS: 121804-28-2
• 化学式: C₁₇H₂₁N
• 分子量: 239.36
• InChiKey: QLIXELVDAZRBLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-Biphenyl-4-ylmethyl-butylamine 在 aluminium hydride 作用下， 以 乙醚 为溶剂， 生成 (1-Biphenyl-4-ylmethyl-butyl)-propyl-amine
  参考文献：
  名称：

  Structure–activity studies leading to (−)1-(Benzofuran-2-yl)-2-propylaminopentane, ((−)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of Catecholamines and Serotonin in the brain

  摘要：

  The catecholaminergic and serotoninergic neurons in the brain change their performance according to the physiological need via a catecholaminergic/serotoninergic activity enhancer (CAE/SAE) mechanism. Phenylethylamine (PEA), tyramine and tryptamine are the presently known endogenous CAE/SAE substances which enhance the impulse propagation mediated release of catecholamines and serotonin in the brain. A PEA derivative, (-)deprenyl (selegiline), known as a selective inhibitor of MAO-B, is for the time being the only CAE/SAE substance in clinical use. Aiming to develop a selective CAE/SAE substance much more potent than (-)deprenyl, a series of new 1-aryl-2-alkylaminoalkanes, structurally unrelated to PEA and the amphetamines, was designed and prepared. Among them, (-)1-(benzofuran-2-yl)-2-propylaminopentane ((-)BPAP) was selected as a promising candidate substance for further studies. (-)BPAP significantly enhanced in rats the impulse propagation mediated release of catecholamines and serotonin in the brain 30 min after acute injection of 0.36 nmol/kg sc. In the shuttle box, (-)BPAP was in rats about 130 times more potent than (-)deprenyl in antagonizing tetrabenazine induced inhibition of performance. (-)BPAP protected cultured hippocampal neurons from the neurotoxic effect of P-amyloid in 10(-14)-10(-15) concentration. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00002-5
• 作为产物：
  描述：

  在 lithium aluminium tetrahydride 作用下， 生成 1-Biphenyl-4-ylmethyl-butylamine
  参考文献：
  名称：

  Structure–activity studies leading to (−)1-(Benzofuran-2-yl)-2-propylaminopentane, ((−)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of Catecholamines and Serotonin in the brain

  摘要：

  The catecholaminergic and serotoninergic neurons in the brain change their performance according to the physiological need via a catecholaminergic/serotoninergic activity enhancer (CAE/SAE) mechanism. Phenylethylamine (PEA), tyramine and tryptamine are the presently known endogenous CAE/SAE substances which enhance the impulse propagation mediated release of catecholamines and serotonin in the brain. A PEA derivative, (-)deprenyl (selegiline), known as a selective inhibitor of MAO-B, is for the time being the only CAE/SAE substance in clinical use. Aiming to develop a selective CAE/SAE substance much more potent than (-)deprenyl, a series of new 1-aryl-2-alkylaminoalkanes, structurally unrelated to PEA and the amphetamines, was designed and prepared. Among them, (-)1-(benzofuran-2-yl)-2-propylaminopentane ((-)BPAP) was selected as a promising candidate substance for further studies. (-)BPAP significantly enhanced in rats the impulse propagation mediated release of catecholamines and serotonin in the brain 30 min after acute injection of 0.36 nmol/kg sc. In the shuttle box, (-)BPAP was in rats about 130 times more potent than (-)deprenyl in antagonizing tetrabenazine induced inhibition of performance. (-)BPAP protected cultured hippocampal neurons from the neurotoxic effect of P-amyloid in 10(-14)-10(-15) concentration. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00002-5

文献信息

• Neue Phenylethanolamine, deren Verwendung als Arzneimittel und als Leistungsförderer bei Tieren sowie Verfahren zu ihrer Herstellung
  申请人：BOEHRINGER INGELHEIM VETMEDICA GMBH

  公开号：EP0375791A1

  公开（公告）日：1990-07-04

  Die Erfindung betrifft neue Phenylethanolamine der allgemei­nen Formel in der A eine geradkettige oder verzweigte Alkylengruppe, B eine Bindung, eine Alkylengruppe, eine Carbonyl- oder Hy­droxymethylengruppe, R₁ ein Wasserstoffatom, ein Halogenatom oder eine Trifluor­methylgruppe, R₂ ein Wasserstoffatom oder eine Aminogruppe, R₃ eine Cyanogruppe, ein Wasserstoff-, Chlor- oder Brom­atom und R₄ ein Wasserstoff- oder Halogenatom, eine Alkyl-, Hydroxy-, Alkoxy-, Carboxy-, Alkoxycarbonyl-, Aminocarbonyl-, Alkyl­aminocarbonyl- oder Dialkylaminocarbonylgruppe oder eine Alkoxygruppe, die endständig durch eine Carboxy-, Alkoxycar­bonyl-, Aminocarbonyl-, Alkylaminocarbonyl-, Dialkylamino­carbonyl-, Hydroxy-, Alkoxy-, Amino-, Alkylamino-, Dialkyl­amino-, Pyrrolidino-, Piperidino- oder Hexamethylenimino­gruppe substituiert ist, bedeuten, deren optische Isomere und deren Diastereomere sowie deren Säureadditionssalze. Die neuen Verbindungen der Formel I, deren optische Isomere und deren Diastereomere sowie deren Säureadditionssalze, ins­besondere deren physiologisch verträgliche Säureadditions­salze mit anorganischen oder organischen Säuren, weisen wert­volle pharmakologische Eigenschaften auf, nämlich eine Wir­kung auf den Stoffwechsel, vorzugsweise eine blutzuckersen­kende und körperfettreduzierende Wirkung, außerdem können diese als Leistungsförderer bei Tieren eingesetzt werden. Die neuen Verbindungen der obigen allgemeinen Formel I las­sen sich nach an und für sich bekannten Verfahren herstellen.

  本发明涉及通式如下的新型苯乙醇胺 其中 A 是直链或支链亚烷基、 B 是键、亚烷基、羰基或羟甲基、 R₁ 是氢原子、卤素原子或三氟甲基、 R₂ 是氢原子或氨基、 R₃ 一个氰基、一个氢原子、一个氯原子或一个溴原子，以及 R₄ 氢原子或卤素原子、烷基、羟基、烷氧基、羧基、烷氧羰基、氨基羰基、烷基氨基羰基或二烷基氨基羰基或以羧基、烷氧羰基、氨基羰基、烷基氨基羰基或二烷基氨基羰基终止的烷氧基、烷基氨基羰基、二烷基氨基羰基、羟基、烷氧基、氨基、烷基氨基、二烷基氨基、吡咯烷基、哌啶基或六亚甲基氨基、它们的光学异构体和非对映异构体以及它们的酸加成盐。 式 I 的新化合物、它们的光学异构体和非对映异构体以及它们的酸加成盐，特别是它们与无机酸或有机酸的生理相容的酸加成盐，具有宝贵的药理特性，即对新陈代谢有影响，最好是有降血糖和减少体内脂肪的作用，还可用作动物的性能增强剂。 上述通式 I 的新化合物可以通过本身已知的方法生产。
• AMMONIUM CARBOXYLATE COMPOUND, CRYSTAL FORM AND AMORPHOUS SUBSTANCE THEREOF, AND PREPARATION METHOD THEREFOR
  申请人：Wuhan LL Science And Technology Development Co., Ltd.

  公开号：EP3611160A1

  公开（公告）日：2020-02-19

  The present disclosure belongs to the field of chemical synthesis, and in particular relates to an ammonium carboxylate compound, a crystalline form and an amorphous form, and a preparation method thereof. The present disclosure prepares the compound and the crystalline form I and its single crystal, amorphous form and crystalline form II thereof. The compound, the crystalline forms, the single crystal and the amorphous form can stably exist and exhibit good solid forms, suitable for medicine-making. Furthermore, these products possess high purity and less single impurity. Moreover, the preparation methods of the present disclosure are easy to implement due to the simple processes with mild reaction conditions, and could produce products of high yield and high purity without complex purification steps. Furthermore, the preparation methods may facilitate safety, environmental protection, and industrial production.

  本公开属于化学合成领域，尤其涉及一种羧酸铵化合物、结晶形式和无定形形式及其制备方法。本公开制备了化合物和结晶形式 I 及其单晶、无定形形式和结晶形式 II。该化合物、晶型、单晶和非晶型均能稳定存在，并呈现良好的固体形态，适用于制药。此外，这些产品纯度高，单一杂质少。此外，本公开的制备方法工艺简单，反应条件温和，易于实施，无需复杂的纯化步骤即可制得高产率和高纯度的产品。此外，本制备方法还有利于安全、环保和工业生产。
• HURNAUS, RUDOLF;REIFFEN, MANFRED;SAUTER, ROBERT;GRELL, WOLFGANG;RUPPRECHT+
  作者：HURNAUS, RUDOLF、REIFFEN, MANFRED、SAUTER, ROBERT、GRELL, WOLFGANG、RUPPRECHT+

  DOI：——

  日期：——
• HURNAUS, RUDOLF;REIFFEN, MANFRED;SAUTER, ROBERT;GRELL, WOLFGANG;RUPRECHT,+
  作者：HURNAUS, RUDOLF、REIFFEN, MANFRED、SAUTER, ROBERT、GRELL, WOLFGANG、RUPRECHT,+

  DOI：——

  日期：——
• NEUE PHENYLETHANOLAMINE
  申请人：BOEHRINGER INGELHEIM VETMEDICA GMBH

  公开号：EP0400011A1

  公开（公告）日：1990-12-05